<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27556308</article-id><article-id pub-id-type="pmc">5062735</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Clopidogrel use After Myocardial Revascularization: Prevalence,
Predictors, and One-Year Survival Rate</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Prates</surname><given-names>Paulo Roberto L.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Judson B.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mehta</surname><given-names>Rajendra H.</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>Susanna R.</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Laine</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Peter K.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Newby</surname><given-names>L. Kristin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kalil</surname><given-names>Renato A. K.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Alexander</surname><given-names>John H.</given-names></name><degrees>MD, MHS</degrees><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>Renato D.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Cardiovascular Surgery, Instituto de
Cardiologia-Funda&#x000e7;&#x000e3;o Universit&#x000e1;ria de Cardiologia, Porto
Alegre, RS, Brazil.</aff><aff id="aff2"><label>2</label>Clinical Research Center- Instituto de
Cardiologia-Funda&#x000e7;&#x000e3;o Universit&#x000e1;ria de Cardiologia, Porto
Alegre, RS, Brazil.</aff><aff id="aff3"><label>3</label>Department of Surgery, Division of Cardiovascular and
Thoracic Surgery, Duke University Medical Center, Durham, NC.</aff><aff id="aff4"><label>4</label>Department of Medicine, Division of Cardiology, Duke
University Medical Center, Durham, NC.</aff><aff id="aff5"><label>5</label>Duke Clinical Research Institute, Durham, NC.</aff><author-notes><corresp id="c1">Correspondence Address: Renato D. Lopes, Duke Clinical Research
Institute, Box 3850, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC
27705. E-mail: <email>renato.lopes@duke.edu</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2016</year></pub-date><volume>31</volume><issue>2</issue><fpage>106</fpage><lpage>114</lpage><history><date date-type="received"><day>08</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>3</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Antiplatelet therapy after coronary artery bypass graft (CABG) has been used.
Little is known about the predictors and efficacy of clopidogrel in this
scenario.</p></sec><sec><title>Objective</title><p>Identify predictors of clopidogrel following CABG.</p></sec><sec><title>Methods</title><p>We evaluated 5404 patients who underwent CABG between 2000 and 2009 at Duke
University Medical Center. We excluded patients undergoing concomitant valve
surgery, those who had postoperative bleeding or death before discharge.
Postoperative clopidogrel was left to the discretion of the attending
physician. Adjusted risk for 1-year mortality was compared between patients
receiving and not receiving clopidogrel during hospitalization after
undergoing CABG.</p></sec><sec><title>Results</title><p>At hospital discharge, 931 (17.2%) patients were receiving clopidogrel.
Comparing patients not receiving clopidogrel at discharge, users had more
comorbidities, including hyperlipidemia, hypertension, heart failure,
peripheral arterial disease and cerebrovascular disease. Patients who
received aspirin during hospitalization were less likely to receive
clopidogrel at discharge (<italic>P</italic>&#x02264;0.0001). Clopidogrel was
associated with similar 1-year mortality compared with those who did not use
clopidogrel (4.4% <italic>vs.</italic> 4.5%, <italic>P</italic>=0.72). There
was, however, an interaction between the use of cardiopulmonary bypass and
clopidogrel, with lower 1-year mortality in patients undergoing off-pump
CABG who received clopidogrel, but not those undergoing conventional CABG
(2.6% <italic>vs</italic> 5.6%, <italic>P</italic> Interaction = 0.032).</p></sec><sec><title>Conclusion</title><p>Clopidogrel was used in nearly one-fifth of patients after CABG. Its use was
not associated with lower mortality after 1 year in general, but lower
mortality rate in those undergoing off-pump CABG. Randomized clinical trials
are needed to determine the benefit of routine use of clopidogrel in
CABG.</p></sec></abstract><kwd-group><kwd>Myocardial Revascularization</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Blood Platelets</kwd></kwd-group><funding-group><award-group><funding-source>National Institutes of Health Cardiothoracic Surgical Trials
Network</funding-source><award-id>U01-HL088953</award-id></award-group><funding-statement>Drs. Williams, Smith, and Alexander are supported in part by
grant U01-HL088953 from the National Institutes of Health Cardiothoracic
Surgical Trials Network.</funding-statement></funding-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">CABG</td><td rowspan="1" colspan="1">= Coronary artery bypass graft</td></tr><tr><td valign="top" rowspan="1" colspan="1">CI</td><td rowspan="1" colspan="1">= Confidence interval</td></tr><tr><td valign="top" rowspan="1" colspan="1">CURE</td><td rowspan="1" colspan="1">= Clopidogrel in unstable angina to prevent recurrent ischemic
Events</td></tr><tr><td valign="top" rowspan="1" colspan="1">HR</td><td rowspan="1" colspan="1">= Hazard risk</td></tr><tr><td valign="top" rowspan="1" colspan="1">PCI</td><td rowspan="1" colspan="1">= Percutaneous coronary intervention</td></tr><tr><td valign="top" rowspan="1" colspan="1">PREVENT IV</td><td rowspan="1" colspan="1">= Project of Ex-vivo Vein graft ENgineering via Transfection IV</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Antiplatelet therapy is beneficial in secondary prevention following coronary artery
bypass graft (CABG) surgery; however, there is no consensus about when to initiate
therapy, how to dose, or the optimal combination of agents<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Clopidogrel also reduces ischemic events and mortality in
patients with coronary and peripheral arterial disease<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. While the
use of aspirin after CABG surgery is widespread<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>,
clopidogrel, the most commonly used P2Y<sub>12</sub> inhibitor, in addition to
aspirin, has been used less often than aspirin alone<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Although it has been shown that antiplatelet therapy improves the patency of venous
grafts<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>, little
is known about which patients are receiving clopidogrel after CABG surgery or about
its association with patient outcomes. In this large singlecenter study we described
the clinical and surgical characteristics and predictors of patients receiving
clopidogrel following CABG surgery, determined the rates of clopidogrel use after 1
year, and compared the 1-year risk-adjusted mortality in patients receiving and not
receiving clopidogrel.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Patients</title><p>We evaluated 6588 patients undergoing CABG surgery between 2000 and 2007 at Duke
University Medical Center (Durham, NC, USA). A total of 815 patients were
excluded for concomitant valve surgery, 177 were excluded for in-hospital
reoperation for bleeding or anticoagulation complications, 188 died prior to
discharge, and 4 additional patients who had undergone CABG surgery within 9
days were excluded, resulting in a final sample size of 5404. Patients
undergoing urgent or elective procedures were included. This study was approved
by the Duke University Health System Institutional Review Board. The requirement
for individual consent was waived. All patients undergoing surgical procedures
signed an informed consent form according to the data collected during
hospitalization which can be used in research.</p></sec><sec><title>Surgical Procedures</title><p>On- and off-pump CABG procedures were performed during the study period,
including both urgent and elective procedures. All patients were operated by the
same group of surgeons that consists of 19 professionals. After median
sternotomy, patients underwent conventional CABG surgery with the use of
internal mammary arteries whenever possible. When performed on pump CABG,
standard cardiopulmonary bypass was used, typically with both anterograde and
retrograde cold blood cardioplegia.</p></sec><sec><title>Clinical Follow-Up</title><p>Discharge clopidogrel use was determined by in-hospital medication records, that
was found in the electronic medical record, and was defined as administration at
any time the day after surgery through the date of discharge. The files were
accessed by the institution's research group. In addition to clinical data
collected during patient visits, medication use and survival were determined
using self-administered mailed questionnaires and telephone follow-up for those
who did not return questionnaires. Deaths reported by Duke hospitals, the
National Death Index, and the Social Security Death Index were used to confirm
or supplement the follow-up surveys for mortality information. These actions
were also performed by the institution's research group. Operative mortality was
defined as death occurring within 30 days of the index procedure or before
discharge.</p></sec><sec><title>Statistical Analyses</title><p>Summary statistics were expressed as medians (25<sup>th</sup>, 75<sup>th</sup>
percentiles) for continuous variables and numbers (percentage) for categorical
variables. Baseline and in-hospital patient characteristics for those who did
and did not receive in-hospital clopidogrel following CABG surgery were compared
using the Wilcoxon rank sum test for continuous variables and chisquare or
Fisher's exact tests for categorical variables. Because of recent findings
demonstrating differences between patients undergoing on- and off-pump CABG
surgery<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>,
unadjusted Kaplan-Meier rates for 1-year survival are shown for the 4-level
stratification of patients who did and did not receive clopidogrel and had
on-pump <italic>versus</italic> off-pump CABG surgery.</p><p>Multivariable logistic regression was used to determine the association between
baseline and in-hospital demographics and clinical factors with in-hospital
clopidogrel use following CABG surgery. All variables as well as their
interactions with on- and off-pump CABG surgery were considered for inclusion
using backward elimination with a requirement of alpha &#x0003c;0.05 for retention
(<xref ref-type="table" rid="t1">Tables 1</xref> and <xref ref-type="table" rid="t2">2</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics according to clopidogrel use after CABG.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">All Patients (N=5404)</th><th align="center" rowspan="1" colspan="1">No Clopidogrel at Discharge (N=4473)</th><th align="center" rowspan="1" colspan="1">Clopidogrel at Discharge (N=931)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Age, median (25<sup>th</sup>, 75<sup>th</sup>), yrs<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">64 (56.72)</td><td align="center" rowspan="1" colspan="1">64 (56.72)</td><td align="center" rowspan="1" colspan="1">63 (55.72)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Female sex, no. (%) <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">1593 (29.5)</td><td align="center" rowspan="1" colspan="1">1276 (28.5)</td><td align="center" rowspan="1" colspan="1">317 (34.0)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">White race, no. (%)</td><td align="center" rowspan="1" colspan="1">4130 (77.5)</td><td align="center" rowspan="1" colspan="1">3413 (77.4)</td><td align="center" rowspan="1" colspan="1">717 (78.4)</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Weight, median (25<sup>th</sup>, 75<sup>th</sup>), kg</td><td align="center" rowspan="1" colspan="1">84 (73.97)</td><td align="center" rowspan="1" colspan="1">85 (74.97)</td><td align="center" rowspan="1" colspan="1">83 (73.96)</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Medical history, no. (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypertension</td><td align="center" rowspan="1" colspan="1">4272 (79.1)</td><td align="center" rowspan="1" colspan="1">3499 (78.2)</td><td align="center" rowspan="1" colspan="1">773 (83.0)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diabetes mellitus <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">1984 (36.7)</td><td align="center" rowspan="1" colspan="1">1632 (36.5)</td><td align="center" rowspan="1" colspan="1">352 (37.8)</td><td align="center" rowspan="1" colspan="1">0.45</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Smoking status</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Current</td><td align="center" rowspan="1" colspan="1">1485 (29.5)</td><td align="center" rowspan="1" colspan="1">1242 (29.9)</td><td align="center" rowspan="1" colspan="1">243 (27.5)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Former</td><td align="center" rowspan="1" colspan="1">1431 (28.4)</td><td align="center" rowspan="1" colspan="1">1127 (27.2)</td><td align="center" rowspan="1" colspan="1">304 (34.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Never</td><td align="center" rowspan="1" colspan="1">2115 (42.0)</td><td align="center" rowspan="1" colspan="1">1779 (42.9)</td><td align="center" rowspan="1" colspan="1">336 (38.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hyperlipidemia</td><td align="center" rowspan="1" colspan="1">3843 (71.1)</td><td align="center" rowspan="1" colspan="1">3136 (70.1)</td><td align="center" rowspan="1" colspan="1">707 (75.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Chronic lung disease <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">611 (11.3)</td><td align="center" rowspan="1" colspan="1">507 (11.3)</td><td align="center" rowspan="1" colspan="1">104 (11.2)</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Any prior MI <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">2738 (50.7)</td><td align="center" rowspan="1" colspan="1">2252 (50.3)</td><td align="center" rowspan="1" colspan="1">486 (52.2)</td><td align="center" rowspan="1" colspan="1">0.30</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Recent MI (30 days)</td><td align="center" rowspan="1" colspan="1">1670 (34.2)</td><td align="center" rowspan="1" colspan="1">1397 (34.5)</td><td align="center" rowspan="1" colspan="1">273 (33.1)</td><td align="center" rowspan="1" colspan="1">0.43</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior PCI</td><td align="center" rowspan="1" colspan="1">838 (15.5)</td><td align="center" rowspan="1" colspan="1">663 (14.8)</td><td align="center" rowspan="1" colspan="1">175 (18.8)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior CABG</td><td align="center" rowspan="1" colspan="1">238 (4.4)</td><td align="center" rowspan="1" colspan="1">177 (4.0)</td><td align="center" rowspan="1" colspan="1">61 (6.6)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior valve procedure</td><td align="center" rowspan="1" colspan="1">36 (0.7)</td><td align="center" rowspan="1" colspan="1">30 (0.7)</td><td align="center" rowspan="1" colspan="1">6 (0.6)</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CHF within prior 2 weeks <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">865 (16.0)</td><td align="center" rowspan="1" colspan="1">743 (16.6)</td><td align="center" rowspan="1" colspan="1">122 (13.1)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;History of cerebrovascular disease <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">720 (13.3)</td><td align="center" rowspan="1" colspan="1">576 (12.9)</td><td align="center" rowspan="1" colspan="1">144 (15.5)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;History of peripheral vascular disease <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">900 (16.7)</td><td align="center" rowspan="1" colspan="1">724 (16.2)</td><td align="center" rowspan="1" colspan="1">176 (18.9)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Patient currently on dialysis</td><td align="center" rowspan="1" colspan="1">111 (2.1)</td><td align="center" rowspan="1" colspan="1">95 (2.1)</td><td align="center" rowspan="1" colspan="1">16 (1.7)</td><td align="center" rowspan="1" colspan="1">0.43</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Renal failure <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">56 (1.0)</td><td align="center" rowspan="1" colspan="1">48 (1.1)</td><td align="center" rowspan="1" colspan="1">8 (0.9)</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cardiogenic shock during the procedure</td><td align="center" rowspan="1" colspan="1">15 (0.3)</td><td align="center" rowspan="1" colspan="1">15 (0.3)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Presenting features</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Creatinine (most recent in past 60 days), median
(25<sup>th</sup>, 75<sup>th</sup>) <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">1.0 (0.9, 1.2)</td><td align="center" rowspan="1" colspan="1">1.0 (0.9, 1.2)</td><td align="center" rowspan="1" colspan="1">1.0 (0.9 - 1.2)</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;GFR (most recent in past 60 days), median (25<sup>th</sup>,
75<sup>th</sup>) <xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">77 (63, 92)</td><td align="center" rowspan="1" colspan="1">77 (63, 91)</td><td align="center" rowspan="1" colspan="1">78 (63 - 93)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;EF (most recent in past 60 days), median (25<sup>th</sup>,
<sup>75th</sup>)*</td><td align="center" rowspan="1" colspan="1">51 (40, 71)</td><td align="center" rowspan="1" colspan="1">51 (40, 68)</td><td align="center" rowspan="1" colspan="1">51 (43 - 75)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Number of vessels &#x02265; 50% stenosed, no. (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;0</td><td align="center" rowspan="1" colspan="1">19 (0.4)</td><td align="center" rowspan="1" colspan="1">17 (0.4)</td><td align="center" rowspan="1" colspan="1">2 (0.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;1</td><td align="center" rowspan="1" colspan="1">296 (5.5)</td><td align="center" rowspan="1" colspan="1">215 (4.8)</td><td align="center" rowspan="1" colspan="1">81 (8.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;2</td><td align="center" rowspan="1" colspan="1">964 (17.8)</td><td align="center" rowspan="1" colspan="1">783 (17.5)</td><td align="center" rowspan="1" colspan="1">181 (19.4)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;3</td><td align="center" rowspan="1" colspan="1">4125 (76.3)</td><td align="center" rowspan="1" colspan="1">3458 (77.3)</td><td align="center" rowspan="1" colspan="1">667 (71.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left main disease &#x0003e; 50%, no. (%)</td><td align="center" rowspan="1" colspan="1">1534 (28.4)</td><td align="center" rowspan="1" colspan="1">1252 (28.0)</td><td align="center" rowspan="1" colspan="1">282 (30.3)</td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Preoperative antiplatelet agents, no. (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Aspirin administered prior to CABG</td><td align="center" rowspan="1" colspan="1">3426 (63.4)</td><td align="center" rowspan="1" colspan="1">2844 (63.6)</td><td align="center" rowspan="1" colspan="1">582 (62.5)</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Clopidogrel administered prior to CABG</td><td align="center" rowspan="1" colspan="1">400 (7.4)</td><td align="center" rowspan="1" colspan="1">297 (6.6)</td><td align="center" rowspan="1" colspan="1">103 (11.1)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Included in multivariable model for mortality.</p></fn><fn id="TFN2"><p>CABG=coronary artery bypass grafting; CHF=congestive heart failure;
EF=ejection fraction; GFR=glomerular filtration rate; MI=myocardial
infarction; PCI=percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Operative and postoperative characteristics according to clopidogrel use
after CABG.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="center" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">All Patients (N=5404)</th><th align="center" valign="top" rowspan="1" colspan="1">No Clopidogrel at Discharge
(N=4473)</th><th align="center" valign="top" rowspan="1" colspan="1">Clopidogrel at Discharge
(N=931)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Surgery type, no. (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Elective</td><td align="center" rowspan="1" colspan="1">1487 (27.5)</td><td align="center" rowspan="1" colspan="1">1306 (29.2)</td><td align="center" rowspan="1" colspan="1">181 (19.4)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Emergent</td><td align="center" rowspan="1" colspan="1">299 (5.5)</td><td align="center" rowspan="1" colspan="1">246 (5.5)</td><td align="center" rowspan="1" colspan="1">53 (5.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Urgent</td><td align="center" rowspan="1" colspan="1">3618 (67.0)</td><td align="center" rowspan="1" colspan="1">2921 (65.3)</td><td align="center" rowspan="1" colspan="1">697 (74.9)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left or right IMA, no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">4940 (91.4)</td><td align="center" rowspan="1" colspan="1">4141 (92.6)</td><td align="center" rowspan="1" colspan="1">799 (85.8)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;SVG harvested endoscopically, no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">4948 (98.0)</td><td align="center" rowspan="1" colspan="1">4129 (98.1)</td><td align="center" rowspan="1" colspan="1">819 (97.7)</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;On-pump surgery, no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">4614 (85.4)</td><td align="center" rowspan="1" colspan="1">4061 (90.8)</td><td align="center" rowspan="1" colspan="1">553 (59.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cross-clamp time, median (25<sup>th</sup>,
75<sup>th</sup>)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">60 (39, 80)</td><td align="center" rowspan="1" colspan="1">61 (43, 80)</td><td align="center" rowspan="1" colspan="1">44 (0, 78)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Perfusion time, median (25<sup>th</sup>,
75<sup>th</sup>)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">109 (83, 135)</td><td align="center" rowspan="1" colspan="1">110 (88, 134)</td><td align="center" rowspan="1" colspan="1">94 (0, 135)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Number of grafts, no. (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1</td><td align="center" rowspan="1" colspan="1">280 (5.2)</td><td align="center" rowspan="1" colspan="1">199 (4.4)</td><td align="center" rowspan="1" colspan="1">81 (8.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2</td><td align="center" rowspan="1" colspan="1">820 (15.2)</td><td align="center" rowspan="1" colspan="1">636 (14.2)</td><td align="center" rowspan="1" colspan="1">184 (19.8)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3</td><td align="center" rowspan="1" colspan="1">2363 (43.7)</td><td align="center" rowspan="1" colspan="1">1982 (44.3)</td><td align="center" rowspan="1" colspan="1">381 (40.9)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265;4</td><td align="center" rowspan="1" colspan="1">1941 (35.9)</td><td align="center" rowspan="1" colspan="1">1656 (37.0)</td><td align="center" rowspan="1" colspan="1">285 (30.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Worst target artery quality, no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Good</td><td align="center" rowspan="1" colspan="1">2094 (39.2)</td><td align="center" rowspan="1" colspan="1">1843 (41.6)</td><td align="center" rowspan="1" colspan="1">251 (27.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Fair</td><td align="center" rowspan="1" colspan="1">2298 (43.0)</td><td align="center" rowspan="1" colspan="1">1898 (42.8)</td><td align="center" rowspan="1" colspan="1">400 (44.2)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Poor</td><td align="center" rowspan="1" colspan="1">946 (17.7)</td><td align="center" rowspan="1" colspan="1">692 (15.6)</td><td align="center" rowspan="1" colspan="1">254 (28.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Worst graft quality, no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Good</td><td align="center" rowspan="1" colspan="1">3916 (73.6)</td><td align="center" rowspan="1" colspan="1">3359 (76.0)</td><td align="center" rowspan="1" colspan="1">557 (61.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Fair</td><td align="center" rowspan="1" colspan="1">1206 (22.7)</td><td align="center" rowspan="1" colspan="1">911 (20.6)</td><td align="center" rowspan="1" colspan="1">295 (32.6)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Poor</td><td align="center" rowspan="1" colspan="1">202 (3.8)</td><td align="center" rowspan="1" colspan="1">150 (3.4)</td><td align="center" rowspan="1" colspan="1">52 (5.8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Type of graft, no. (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left saphenous vein</td><td align="center" rowspan="1" colspan="1">4716 (87.3)</td><td align="center" rowspan="1" colspan="1">3953 (88.4)</td><td align="center" rowspan="1" colspan="1">763 (82.0)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Right saphenous vein</td><td align="center" rowspan="1" colspan="1">1161 (21.5)</td><td align="center" rowspan="1" colspan="1">907 (20.3)</td><td align="center" rowspan="1" colspan="1">254 (27.3)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Both left &#x00026; right saphenous veins</td><td align="center" rowspan="1" colspan="1">785 (14.5)</td><td align="center" rowspan="1" colspan="1">614 (13.7)</td><td align="center" rowspan="1" colspan="1">171 (18.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left internal thoracic artery</td><td align="center" rowspan="1" colspan="1">4875 (90.2)</td><td align="center" rowspan="1" colspan="1">4090 (91.4)</td><td align="center" rowspan="1" colspan="1">785 (84.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Right internal thoracic artery</td><td align="center" rowspan="1" colspan="1">188 (3.5)</td><td align="center" rowspan="1" colspan="1">156 (3.5)</td><td align="center" rowspan="1" colspan="1">32 (3.4)</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Both left &#x00026; right internal thoracic arteries</td><td align="center" rowspan="1" colspan="1">123 (2.3)</td><td align="center" rowspan="1" colspan="1">104 (2.3)</td><td align="center" rowspan="1" colspan="1">19 (2.0)</td><td align="center" rowspan="1" colspan="1">0.60</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left radial artery</td><td align="center" rowspan="1" colspan="1">305 (5.6)</td><td align="center" rowspan="1" colspan="1">201 (4.5)</td><td align="center" rowspan="1" colspan="1">104 (11.2)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Right radial artery</td><td align="center" rowspan="1" colspan="1">50 (0.9)</td><td align="center" rowspan="1" colspan="1">37 (0.8)</td><td align="center" rowspan="1" colspan="1">13 (1.4)</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Both left &#x00026; right radial arteries</td><td align="center" rowspan="1" colspan="1">17 (0.3)</td><td align="center" rowspan="1" colspan="1">12 (0.3)</td><td align="center" rowspan="1" colspan="1">5 (0.5)</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Length of stay, median (25<sup>th</sup>,
75<sup>th</sup>)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">9 (7, 12)</td><td align="center" rowspan="1" colspan="1">9 (7, 12)</td><td align="center" rowspan="1" colspan="1">9 (7, 12)</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Patient discharged on warfarin, no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">208 (3.8)</td><td align="center" rowspan="1" colspan="1">178 (4.0)</td><td align="center" rowspan="1" colspan="1">30 (3.2)</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Aspirin after surgery and before discharge, no. (%)*</td><td align="center" rowspan="1" colspan="1">5303 (98.1)</td><td align="center" rowspan="1" colspan="1">4403 (98.4)</td><td align="center" rowspan="1" colspan="1">900 (96.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;MI occurs after surgery and before discharge, no. (%)*</td><td align="center" rowspan="1" colspan="1">13 (0.2)</td><td align="center" rowspan="1" colspan="1">5 (0.1)</td><td align="center" rowspan="1" colspan="1">8 (0.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cerebrovascular accident after surgery and before discharge,
no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">112 (2.1)</td><td align="center" rowspan="1" colspan="1">91 (2.0)</td><td align="center" rowspan="1" colspan="1">21 (2.3)</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Atrial fibrillation before discharge, no. (%)<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">930 (17.2)</td><td align="center" rowspan="1" colspan="1">794 (17.8)</td><td align="center" rowspan="1" colspan="1">136 (14.6)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p>Included in multivariable model for mortality.</p></fn><fn id="TFN4"><p>IMA=internal mammary artery; MI=myocardial infarction; SVG=saphenous
vein graft</p></fn></table-wrap-foot></table-wrap><p>Cox proportional hazards analysis was performed to evaluate the association
between post-CABG clopidogrel use and 1-year mortality. We adjusted for
covariates identified in the PRoject of Ex-vivo Vein graft ENgineering via
Transfection IV (PREVENT IV) trial mortality model<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>, developed in a similar CABG population, and
included the most closely related variables available in our dataset. In
addition, we also adjusted for aspirin use after CABG surgery, warfarin use at
discharge, on- and off-pump CABG-surgery, in-hospital cerebrovascular accident
and renal failure. Adjusted survival curves are shown for the clopidogrel effect
in the multivariable Cox mortality model. The model was repeated with the
inclusion of the interaction of clopidogrel with on- and off-pump CABG surgery;
adjusted survival curves for this interaction are shown.</p><p>For the multivariable logistic and Cox models, continuous and ordinal variables
were tested for linearity over the log hazard and were transformed as necessary
to meet this modeling assumption. The proportional hazards assumption was
checked for each variable in the mortality model and there were no deviations of
concern. Statistical analyses were performed using SAS version 9.1 (SAS
Institute, Inc., Cary, NC, USA).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study Population and Baseline Characteristics</title><p>Total of 5404 patients who underwent CABG surgery from 2000-2007 where evaluated.
Among these patients, 931 (17.2%) received clopidogrel after CABG surgery.
Patients who received clopidogrel, 789 were alive with complete medication
information after 1 year and 314 (39.8%) were still taking clopidogrel. Among
the patients not taking clopidogrel after surgery, 8.9% (345/3868) were taking
it after 1 year. One-year mortality was related to the use of clopidogrel at any
time in hospital postoperative evolution. The above data add information about
using this medication after discharge.</p><p>Patient baseline characteristics are shown in <xref ref-type="table" rid="t1">Table 1</xref>. When compared with patients who did not receive
clopidogrel, those who did were younger and had more comorbidities including
hyperlipidemia, hypertension, peripheral arterial disease, and cerebrovascular
disease but less heart failure in the prior 2 weeks. They were also more likely
to have undergone prior percutaneous coronary intervention (PCI) or CABG
surgery. Post-CABG clopidogrel users were also more likely to have received
clopidogrel in the preoperative period. Overall, aspirin was used in 98.1% of
patients after CABG surgery (96.7% with and 98.4% without clopidogrel after CABG
surgery).</p></sec><sec><title>Surgical Characteristics</title><p>The main surgical procedure characteristics are shown in <xref ref-type="table" rid="t2">Table 2</xref>. Patients who did not receive clopidogrel more often
underwent elective surgery (29.2% <italic>vs.</italic> 19.4%) while those
receiving clopidogrel more often underwent urgent procedures (65.3%
<italic>vs.</italic> 74.9%). Clopidogrel users were more likely to have bad
quality grafts than patients who did not receive clopidogrel. The hospital
length of stay was similar among the 2 groups.</p><p>In the overall population, 4716 (87.3%) patients had left saphenous vein grafts
harvested, 1161 (21.5%) had right saphenous vein grafts harvested, and 785
(14.5%) had saphenous vein grafts from both left and right legs harvested (<xref ref-type="table" rid="t2">Table 2</xref>). A total of 4875 (90.2%) patients
had a left internal thoracic artery graft, 188 (3.5%) had a right internal
thoracic artery graft, and 123 (2.3%) had both internal thoracic artery grafts.
Left radial grafts were used in 305 (5.6%) patients, 50 (0.9%) patients had a
right radial artery graft, and 17 (0.3%) had both a right and left radial artery
graft. While right saphenous vein grafts and left radial artery grafts were more
commonly used in patients discharged with clopidogrel, left saphenous vein
grafts and left internal thoracic artery grafts were more often used in patients
discharged without clopidogrel (<xref ref-type="table" rid="t2">Table
2</xref>).</p></sec><sec><title>Predictors of Clopidogrel Use</title><p>The predictors of clopidogrel use are shown in <xref ref-type="table" rid="t3">Table 3</xref>. Patients who had worse target artery or graft quality, left
main disease, prolonged perfusion time, clopidogrel before surgery, or prior PCI
were more likely to receive clopidogrel after CABG surgery. Advanced age,
internal mammary artery graft, elective surgery, and aspirin use before surgery
or at discharge were associated with a lower probability of clopidogrel use
following CABG surgery.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Multivariable associations with clopidogrel use after CABG (N=4887).</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Chi-square</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Worst target artery quality, OR for 1 category increase</td><td align="center" rowspan="1" colspan="1">671,789</td><td align="center" rowspan="1" colspan="1">1.70 (1.50, 1.94)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Left or right IMA</td><td align="center" rowspan="1" colspan="1">197,168</td><td align="center" rowspan="1" colspan="1">0.55 (0.42, 0.72)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Worst graft quality, OR for 1 category increase</td><td align="center" rowspan="1" colspan="1">160,361</td><td align="center" rowspan="1" colspan="1">1.36 (1.17, 1.58)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Age, OR for 10-year increase</td><td align="center" rowspan="1" colspan="1">134,104</td><td align="center" rowspan="1" colspan="1">0.86 (0.79, 0.93)</td><td align="center" rowspan="1" colspan="1">0.0003</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Left main disease</td><td align="center" rowspan="1" colspan="1">127,628</td><td align="center" rowspan="1" colspan="1">1.40 (1.16, 1.69)</td><td align="center" rowspan="1" colspan="1">0.0004</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">MI before discharge</td><td align="center" rowspan="1" colspan="1">115,781</td><td align="center" rowspan="1" colspan="1">10.85 (2.75, 42.82)</td><td align="center" rowspan="1" colspan="1">0.0007</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Surgery type (reference is elective)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Emergency</td><td rowspan="2" align="center" colspan="1"> 127,735</td><td align="center" rowspan="1" colspan="1">1.33 (0.88, 1.99)</td><td rowspan="2" align="center" colspan="1"> 0.0017</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Urgent</td><td align="center" rowspan="1" colspan="1">1.52 (1.21, 1.92)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Ejection fraction, OR for 10% increase</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Linear spline &#x02265;67, OR for off pump</td><td rowspan="2" align="center" colspan="1"> 98,291</td><td align="center" rowspan="1" colspan="1">4.10 (2.48, 6.77)</td><td rowspan="2" align="center" colspan="1">0.0017<xref ref-type="table-fn" rid="TFN7">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Linear spline &#x02265;67, OR for on pump</td><td align="center" rowspan="1" colspan="1">1.75 (1.23, 2.49)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Linear spline &#x02264;67</td><td align="center" rowspan="1" colspan="1">47,879</td><td align="center" rowspan="1" colspan="1">0.92 (0.85, 0.99)</td><td align="center" rowspan="1" colspan="1">0.0287</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Number of grafts, OR for off pump</td><td rowspan="2" align="center" colspan="1">88,668</td><td align="center" rowspan="1" colspan="1">1.08 (0.88, 1.32)</td><td rowspan="2" align="center" colspan="1"> 0.0029<xref ref-type="table-fn" rid="TFN7">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Number of grafts, OR for on pump</td><td align="center" rowspan="1" colspan="1">0.75 (0.66, 0.86)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Aspirin at discharge</td><td align="center" rowspan="1" colspan="1">83,606</td><td align="center" rowspan="1" colspan="1">0.46 (0.27, 0.78)</td><td align="center" rowspan="1" colspan="1">0.0038</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Pre-CABG clopidogrel</td><td align="center" rowspan="1" colspan="1">76,374</td><td align="center" rowspan="1" colspan="1">1.52 (1.13, 2.04)</td><td align="center" rowspan="1" colspan="1">0.0057</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Perfusion time, OR for 30-minute increase</td><td align="center" rowspan="1" colspan="1">74,737</td><td align="center" rowspan="1" colspan="1">1.13 (1.04, 1.24)</td><td align="center" rowspan="1" colspan="1">0.0063</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">SVG harvested endoscopically, OR for off pump</td><td rowspan="2" align="center" colspan="1"> 73,470</td><td align="center" rowspan="1" colspan="1">4.66 (1.33, 16.33)</td><td rowspan="2" align="center" colspan="1"> 0.0067<xref ref-type="table-fn" rid="TFN7">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">SVG harvested endoscopically, OR for on pump</td><td align="center" rowspan="1" colspan="1">0.67 (0.36, 1.26)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Congestive heart failure</td><td align="center" rowspan="1" colspan="1">72,702</td><td align="center" rowspan="1" colspan="1">0.71 (0.55, 0.91)</td><td align="center" rowspan="1" colspan="1">0.0070</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Pre-CABG aspirin</td><td align="center" rowspan="1" colspan="1">69,593</td><td align="center" rowspan="1" colspan="1">0.77 (0.63, 0.93)</td><td align="center" rowspan="1" colspan="1">0.0083</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">History of hypertension</td><td align="center" rowspan="1" colspan="1">58,004</td><td align="center" rowspan="1" colspan="1">1.32 (1.05, 1.65)</td><td align="center" rowspan="1" colspan="1">0.0160</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">History of PCI</td><td align="center" rowspan="1" colspan="1">55,437</td><td align="center" rowspan="1" colspan="1">1.31 (1.05, 1.63)</td><td align="center" rowspan="1" colspan="1">0.0185</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Cross-clamp time, OR for 30-minute increase</td><td align="center" rowspan="1" colspan="1">53,599</td><td align="center" rowspan="1" colspan="1">1.18 (1.03, 1.35)</td><td align="center" rowspan="1" colspan="1">0.0206</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Cerebrovascular accident before discharge, OR for off pump</td><td rowspan="2" align="center" colspan="1"> 51,980</td><td align="center" rowspan="1" colspan="1">0.24 (0.05, 1.16)</td><td rowspan="2" align="center" colspan="1"> 0.0226<xref ref-type="table-fn" rid="TFN7">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Cerebrovascular accident before discharge, OR for on pump</td><td align="center" rowspan="1" colspan="1">1.68 (0.96, 2.94)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Atrial fibrillation before discharge</td><td align="center" rowspan="1" colspan="1">51,469</td><td align="center" rowspan="1" colspan="1">0.76 (0.59, 0.96)</td><td align="center" rowspan="1" colspan="1">0.0233</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Discharge warfarin, OR for off pump</td><td rowspan="2" align="center" colspan="1"> 40,785</td><td align="center" rowspan="1" colspan="1">1.63 (0.60, 4.43)</td><td rowspan="2" align="center" colspan="1"> 0.0434<xref ref-type="table-fn" rid="TFN7">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Discharge warfarin, OR for on pump</td><td align="center" rowspan="1" colspan="1">0.50 (0.28, 0.90)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">History of cerebrovascular disease</td><td align="center" rowspan="1" colspan="1">40,576</td><td align="center" rowspan="1" colspan="1">1.28 (1.01, 1.62)</td><td align="center" rowspan="1" colspan="1">0.0440</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>*</label><p><italic>P</italic> value for interaction term of variable with
on/off-pump.</p></fn><fn id="TFN8"><p>CI=confidence interval; IMA=internal mammary artery; MI=myocardial
infarction; OR=odds ratio; PCI=percutaneous coronary intervention;
SVG=saphenous vein graft</p></fn></table-wrap-foot></table-wrap></sec><sec><title>1-Year Mortality</title><p>Clopidogrel use was associated with similar 1-year mortality (4.7%
<italic>vs.</italic> 4.5%, adjusted hazard ratio (HR) 1.08, 95% confidence
interval (CI) 0.73-1.59; <italic>P</italic>=0.70) compared with those not using
clopidogrel (<xref ref-type="table" rid="t4">Table 4</xref>, <xref ref-type="fig" rid="f1">Figure 1</xref>). However, there was an interaction
between use of cardiopulmonary bypass and clopidogrel, with lower 1-year
mortality with clopidogrel in patients undergoing off-pump CABG surgery
(adjusted HR 0.47, 95% CI 0.19-1.13), but not in those undergoing on-pump CABG
surgery (adjusted HR 1.35, 95% CI 0.89-2.05; <italic>P</italic>
interaction=0.032) (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Kaplan-Meier rates for 1-year mortality according clopidogrel use
<italic>versus</italic> not stratified by off and on pump
surgeries.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">Alive</th><th align="left" rowspan="1" colspan="1">Death</th><th align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Off pump</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">No clopidogrel, no. (%)</td><td rowspan="1" colspan="1">392 (95.1)</td><td rowspan="1" colspan="1">20 (4.9)</td><td rowspan="1" colspan="1">412</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Clopidogrel, no. (%)</td><td rowspan="1" colspan="1">368 (97.4)</td><td rowspan="1" colspan="1">10 (2.6)</td><td rowspan="1" colspan="1">378</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">760</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">790</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">On pump<xref ref-type="table-fn" rid="TFN9">*</xref></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">No clopidogrel, no. (%)</td><td rowspan="1" colspan="1">3877* (95.5)</td><td rowspan="1" colspan="1">183 (4.5)</td><td rowspan="1" colspan="1">4060</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Clopidogrel, no. (%)</td><td rowspan="1" colspan="1">521* (94.4)</td><td rowspan="1" colspan="1">31 (5.6)</td><td rowspan="1" colspan="1">552</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">4398</td><td rowspan="1" colspan="1">214</td><td rowspan="1" colspan="1">4612</td></tr></tbody></table><table-wrap-foot><fn id="TFN9"><label>*</label><p>One on-pump patient without and one on-pump patient with clopidogrel
after CABG were censored before the 1-year follow-up period. These
patients are not included in the alive counts after 1 year but are
reflected in the Kaplan-Meier rate.</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>One-year mortality according to the clopidrogel use after CABG.</p></caption><graphic xlink:href="rbccv-31-02-0106-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>One-year mortality according to the clopidrogel use after on-pump and
off-pump CABG.</p></caption><graphic xlink:href="rbccv-31-02-0106-g02"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our study has 2 main findings. First, at Duke University Medical Center,
postoperative clopidogrel is used in almost one-fifth of the patients undergoing
CABG surgery. These patients tend to be sicker and have more comorbidities than
those who do not receive clopidogrel after surgery. We also identified several key
factors associated with clopidogrel use after CABG surgery. Second, clopidogrel use
was associated with similar 1-year mortality compared with those patients not using
it. However, there was an interaction between the use of cardiopulmonary bypass and
clopidogrel, with lower 1-year mortality with clopidogrel among patients undergoing
off-pump CABG surgery and higher 1-year mortality with clopidogrel among those
undergoing on-pump CABG surgery.</p><p>Previous studies have demonstrated the benefit of antiplatelet agents, particularly
aspirin, after CABG surgery, although there is no consensus on when to initiate and
what dose should be used. Moreover, these studies do not directly show the impact of
therapy on mid- and long-term mortality<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>. There are published reports of controlled trials
showing benefit of different antiplatelet therapies, including aspirin
alone<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>, aspirin plus dipyridamole<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>, and aspirin plus sulfinpyrazone<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. More recent studies have
demonstrated improved graft patency with the use of clopidogrel<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. While the success of the surgical procedure is most critical
to the patency of a graft, understanding the relationship between clopidogrel use
and mortality and other hard clinical outcomes is critical.</p><p>Clopidogrel use in patients with acute coronary syndromes demonstrates
benefit<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>.
Treatment with clopidogrel reduced the risk of myocardial infarction and recurrent
ischemia, with a trend toward lower rates of cerebrovascular accident and death from
cardiovascular causes<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Antiplatelet therapy with aspirin has led to improvements in
vein graft patency when started early after CABG<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>. The combination of clopidogrel and aspirin after
off-pump CABG surgery was previously suggested to reduce cardiac events and
mortality<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> as well as
improve graft patency in a single-center trial of 249 patients (91.6% for aspirin
plus clopidogrel <italic>vs.</italic> 85.7% for aspirin alone;
<italic>P</italic>=0.043) <sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>While it remains unknown why some patients received clopidogrel and others did not,
our study identified several factors associated with clopidogrel use following CABG
surgery: target vessel quality, graft quality, age, congestive heart failure,
cerebrovascular accident, prior myocardial infarction, prior PCI, prior CABG
surgery, and aspirin use at hospital discharge. The strongest predictor of
clopidogrel use after CABG surgery was worse target artery quality. Importantly,
almost every patient (98.1%) received aspirin after the CABG surgery and this was
significantly associated with less use of clopidogrel during the hospital stay.
Whether the patients were treated on or off pump, it appears that clopidogrel was
generally chosen for younger patients (perhaps balancing bleeding risks) with poor
target artery quality, cerebrovascular disease, and previous coronary interventions.
Without randomized data on clopidogrel use following CABG surgery, our study
provides insights about potential factors associated with its use that might help
physicians decide when to use clopidogrel in this clinical setting.</p><p>In a subgroup analysis from the PREVENT IV study, in which all patients received
aspirin at hospital discharge, clopidogrel use was associated with a trend for
higher rates of occluded vein grafts during 12-18 months (49% <italic>vs.</italic>
39%; adjusted odds ratio 1.26; <italic>P</italic>=0.08) and with similar composite
rates of death, myocardial infarction, or revascularization (27%
<italic>vs.</italic> 24%; adjusted HR 1.10; <italic>P</italic>=0.38) in 5 years
compared with those without it<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. This study found a significant interaction between use of
cardiopulmonary bypass and clopidogrel. Similarly, in our study, the administration
of clopidogrel during the hospital stay was not associated with overall 1-year
mortality in patients undergoing CABG surgery, even in those cases where an
emergency or urgent surgery was needed. In patients undergoing off-pump surgery, we
found that clopidogrel use was associated with higher 1-year survival; however, in
patients undergoing on-pump surgery, clopidogrel use was associated with higher
1-year mortality.</p><p>Studies show different conclusions regarding the results found when the techniques
compared with and without cardiopulmonary bypass<sup>[<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>. On the
other hand, several investigators have indicated that off-pump CABG surgery may
increase the risk of thrombosis due to augmented thrombotic activity<sup>[<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>. There is a well-known phenomenon of thrombotic activity
following major general surgery and it is expected after major procedures<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. In fact, Mariani et
al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup> demonstrated that
thrombotic activity is increased in the first 24 hours after off-pump surgery.
Clopidogrel appeared to have a role in decreasing clotting and protecting the
patency of anastomoses. In on-pump surgery, there is a well described decrease in
platelet function that could bring benefits for graft patency<sup>[<xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref>]</sup>. This benefit does not occur in off-pump surgery where
platelet function tends to be closer to normal, leaving more room for benefit of an
antiplatelet agent such as clopidogrel. It is known that extracorporeal circulation
leads to a decrease in blood coagulation activity, mainly due to consumption of
factors and reduction of platelet activity<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. This could have a protective impact on patients
undergoing on-pump CABG surgery. In this situation, the pharmacological activity of
clopidogrel may not have as much of a role and this may have contributed to our
findings.</p><p>In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE)
trial, patients randomized to clopidogrel in addition to aspirin had a 20% reduction
in cardiovascular death, myocardial infarction, or cerebrovascular accident in the
9<sup>th</sup> month in the follow-up period. Among patients who underwent CABG
surgery, the apparent benefit of clopidogrel was tempered by a higher major bleeding
rate among clopidogrel-treated patients (9.6% <italic>vs.</italic> 7.5%,
respectively). Importantly, these patients were already on clopidogrel when
undergoing CABG surgery and did not start clopidogrel for the first time after
surgery. Based in large part on the CURE trial data, the current American College of
Cardiology/American Heart Association/Society of Thoracic Surgeons guidelines
recommend withholding therapy for 5 days among acute coronary syndrome patients
requiring CABG surgery<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>.</p><p>At the present time, there are not adequate randomized clinical trial data to
determine whether adding clopidogrel to aspirin prevents adverse clinical outcomes
(death, myocardial infarction, cerebrovascular accident, unstable angina, or
recurrence of angina) after CABG surgery. Despite this, clopidogrel is widely but
inconsistently prescribed in patients after CABG surgery with stable coronary
disease<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, a practice
supported primarily by subgroup analyses and observational data<sup>[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r29" ref-type="bibr">29</xref>,<xref rid="r31" ref-type="bibr">31</xref>]</sup>. In our study,
clopidogrel was used more often in patients with poor graft quality, which suggests
that cardiologists and cardiac surgeons might be using clopidogrel after CABG
surgery in patients with worse coronary disease. While also observational, the data
we present do not support a beneficial effect of dual antiplatelet therapy following
CABG surgery, although there may be some benefit in the off-pump setting.</p><sec><title>Limitations</title><p>Our study has several limitations to consider. First, this is an observational
study and one cannot account for unmeasured confounders. Thus, a cause and
effect relationship between clopidogrel use and mortality cannot be assessed.
Second, this is a single-center study and caution should be taken when
generalizing our results to other institutions or settings. Third, while target
artery quality was measured, other intraoperative technical factors were not
measured and may play a role in identifying candidates for dual antiplatelet
therapy after CABG surgery. Fourth, discharge clopidogrel was determined using
inhospital medication records and it was defined as administration at any time
the day after surgery through the date of discharge. Therefore, the term
"clopidogrel at discharge" is not consistent and does not necessarily means
clopidogrel use at the time of discharge. In addition, we did not have
information on 1-year medication use for all patients. We demonstrated that only
around one-third of the patients who were discharged on clopidogrel were on it
for 1 year, and less than 10% of patients who did not receive clopidogrel at
discharge were on it for 1 year. Unfortunately, we did not collect the reasons
for stopping and starting clopidogrel following CABG surgery. Nonetheless, this
is one of the few studies that was able to describe medication use in 1 year,
which provides important insights about adherence and medication
persistence.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>At our institution, clopidogrel was used in almost one-fifth of patients following
CABG surgery. Its use was not associated with improved overall 1-year survival, yet
may have some benefit among those receiving off-pump CABG. Adequately powered
randomized clinical trials are needed to determine whether there is a role for
routine or selected use of clopidogrel or newer antiplatelet agents after CABG
surgery.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">PRLP</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">JBW</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">RHM</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">SRS</td><td rowspan="1" colspan="1">Statistical analysis; manuscript redaction or critical review of its
content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">LT</td><td rowspan="1" colspan="1">Statistical analysis; manuscript redaction or critical review of its
content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">PKS</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">LKN</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">RAKK</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">JHA</td><td rowspan="1" colspan="1">Conception and design study; analysis and/or data interpretation;
manuscript redaction or critical review of its content; final
manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">RDL</td><td rowspan="1" colspan="1">Conception and design study; analysis and/or data interpretation;
manuscript redaction or critical review of its content; final
manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>None of the other authors have any conflict of interest to report related to this
study.</p></fn><fn fn-type="supported-by"><p>This work was supported by the Duke Clinical Research Institute (DCRI). The DCRI
provided funding for the design, conception, and conduct of the study;
acquisition, analysis, and interpretation of data; preparation, review, or
approval of the manuscript.</p></fn><fn fn-type="other"><p>This study was carried out at the Instituto de Cardiologia do Rio Grande do Sul -
Funda&#x000e7;&#x000e3;o Universit&#x000e1;ria de Cardiologia, Porto Alegre, RS, Brazil.</p></fn><fn fn-type="financial-disclosure"><p>Drs. Williams, Smith, and Alexander are supported in part by grant U01-HL088953
from the National Institutes of Health Cardiothoracic Surgical Trials
Network.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motwani</surname><given-names>JG</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Aortocoronary saphenous vein graft disease: pathogenesis,
predisposition, and prevention</article-title><source>Circulation</source><year>1998</year><volume>97</volume><issue>9</issue><fpage>916</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">9521341</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>S</given-names></name><name><surname>Copeland</surname><given-names>J</given-names></name><name><surname>Moritz</surname><given-names>T</given-names></name><name><surname>Henderson</surname><given-names>W</given-names></name><name><surname>Zadina</surname><given-names>K</given-names></name><name><surname>Ovitt</surname><given-names>T</given-names></name><etal/></person-group><article-title>Long-term graft patency (3 years) after coronary artery surgery.
Effects of aspirin: results of a VA Cooperative study</article-title><source>Circulation</source><year>1994</year><volume>89</volume><issue>3</issue><fpage>1138</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">8124800</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>S</given-names></name><name><surname>Copeland</surname><given-names>J</given-names></name><name><surname>Moritz</surname><given-names>T</given-names></name><name><surname>Henderson</surname><given-names>W</given-names></name><name><surname>Zadina</surname><given-names>K</given-names></name><name><surname>Ovitt</surname><given-names>T</given-names></name><etal/></person-group><article-title>Improvement in early saphenous vein graft patency after coronary
artery bypass surgery with antiplatelet therapy: results of a Veterans
Administration Cooperative Study</article-title><source>Circulation</source><year>1988</year><volume>77</volume><issue>6</issue><fpage>1324</fpage><lpage>1332</lpage><pub-id pub-id-type="pmid">3286040</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi</surname><given-names>R</given-names></name><name><surname>Bakaeen</surname><given-names>FG</given-names></name><name><surname>Uberoi</surname><given-names>A</given-names></name><name><surname>Ardehali</surname><given-names>A</given-names></name><name><surname>Baltz</surname><given-names>JH</given-names></name><name><surname>Hattler</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effect of clopidogrel use post coronary artery bypass surgery on
graft patency</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>97</volume><issue>1</issue><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">24206971</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Mehta</surname><given-names>SR</given-names></name><name><surname>Chrolavicius</surname><given-names>S</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>KK</given-names></name><collab>Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial
Investigators</collab></person-group><article-title>Effects of clopidogrel in addition to aspirin in patients with
acute coronary syndromes without ST-segment elevation</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>7</issue><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">11519503</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>CAPRIE Steering Committee</collab></person-group><article-title>A randomised, blinded, trial of clopidogrel versus aspirin in
patients at risk of ischaemic events (CAPRIE)</article-title><source>Lancet</source><year>1996</year><volume>348</volume><issue>9038</issue><fpage>1329</fpage><lpage>1339</lpage><pub-id pub-id-type="pmid">8918275</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Pi</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Aspirin plus clopidogrel therapy increases early venous graft
patency after coronary artery bypass surgery a single-center, randomized,
controlled trial</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><issue>20</issue><fpage>1639</fpage><lpage>1643</lpage><pub-id pub-id-type="pmid">21050973</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitchett</surname><given-names>D</given-names></name><name><surname>Eikelboom</surname><given-names>J</given-names></name><name><surname>Fremes</surname><given-names>S</given-names></name><name><surname>Mazer</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Bittira</surname><given-names>B</given-names></name><etal/></person-group><article-title>Dual antiplatelet therapy in patients requiring urgent coronary
artery bypass grafting surgery: a position statement of the Canadian
Cardiovascular Society</article-title><source>Can J Cardiol</source><year>2009</year><volume>25</volume><issue>12</issue><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">19960127</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>RL</given-names></name><name><surname>Schacky</surname><given-names>CV</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Meister</surname><given-names>W</given-names></name><name><surname>Kotzur</surname><given-names>J</given-names></name><name><surname>Reichardt</surname><given-names>B</given-names></name><etal/></person-group><article-title>Improved aortocoronary bypass patency by low-dose aspirin (100 mg
daily). Effects on platelet aggregation and thromboxane
formation</article-title><source>Lancet</source><year>1984</year><volume>1</volume><issue>8389</issue><fpage>1261</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">6144975</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><article-title>Collaborative overview of randomised trials of antiplatelet
therapy. II: Maintenance of vascular graft or arterial patency by
antiplatelet therapy. Antiplatelet Trialists' Collaboration</article-title><source>BMJ</source><year>1994</year><volume>308</volume><issue>6922</issue><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">8312766</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>A</given-names></name><name><surname>Alexander</surname><given-names>JH</given-names></name><name><surname>Hafley</surname><given-names>GE</given-names></name><name><surname>Graham</surname><given-names>SH</given-names></name><name><surname>Mehta</surname><given-names>RH</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Outcomes associated with the use of secondary prevention
medications after coronary artery bypass graft surgery</article-title><source>Ann Thorac Surg</source><year>2007</year><volume>83</volume><issue>3</issue><fpage>993</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">17307447</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurbuz</surname><given-names>AT</given-names></name><name><surname>Zia</surname><given-names>AA</given-names></name><name><surname>Vuran</surname><given-names>AC</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Aytac</surname><given-names>A</given-names></name></person-group><article-title>Postoperative clopidogrel improves mid-term outcome after
off-pump coronary artery bypass graft surgery: a prospective
study</article-title><source>Eur J Cardiothorac Surg</source><year>2006</year><volume>29</volume><issue>2</issue><fpage>190</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">16388957</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Lopes</surname><given-names>RD</given-names></name><name><surname>Hafley</surname><given-names>GE</given-names></name><name><surname>Ferguson Jr</surname><given-names>TB</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Relationship between postoperative clopidogrel use and subsequent
angiographic and clinical outcomes following coronary artery bypass
grafting</article-title><source>J Thromb Thrombolysis</source><year>2013</year><volume>36</volume><issue>4</issue><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">23543398</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>BG</given-names></name><name><surname>Cukingnan</surname><given-names>RA</given-names></name><name><surname>DeRouen</surname><given-names>T</given-names></name><name><surname>Goede</surname><given-names>LV</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Fee</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Improved graft patency in patients treated with
platelet-inhibiting therapy after coronary bypass surgery</article-title><source>Circulation</source><year>1985</year><volume>72</volume><issue>1</issue><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">3874009</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesebro</surname><given-names>JH</given-names></name><name><surname>Clements</surname><given-names>IP</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Elveback</surname><given-names>LR</given-names></name><name><surname>Smith</surname><given-names>HC</given-names></name><name><surname>Bardsley</surname><given-names>WT</given-names></name><etal/></person-group><article-title>A platelet-inhibitor-drug trial in coronary-artery bypass
operations: benefit of perioperative dipyridamole and aspirin therapy on
early postoperative vein-graft patency</article-title><source>N Engl J Med</source><year>1982</year><volume>307</volume><issue>2</issue><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">7045659</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesebro</surname><given-names>JH</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Elveback</surname><given-names>LR</given-names></name><name><surname>Clements</surname><given-names>IP</given-names></name><name><surname>Smith</surname><given-names>HC</given-names></name><name><surname>Holmes</surname><given-names>DR Jr</given-names></name><etal/></person-group><article-title>Effect of dipyridamole and aspirin on late vein-graft patency
after coronary bypass operations</article-title><source>N Engl J Med</source><year>1984</year><volume>310</volume><issue>4</issue><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">6361561</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baur</surname><given-names>HR</given-names></name><name><surname>VanTassel</surname><given-names>RA</given-names></name><name><surname>Pierach</surname><given-names>CA</given-names></name><name><surname>Gobel</surname><given-names>FL</given-names></name></person-group><article-title>Effects of sulfinpyrazone on early graft closure after myocardial
revascularization</article-title><source>Am J Cardiol</source><year>1982</year><volume>49</volume><issue>2</issue><fpage>420</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">7058755</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricoci</surname><given-names>P</given-names></name><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Mulgund</surname><given-names>J</given-names></name><name><surname>Newby</surname><given-names>LK</given-names></name><name><surname>Smith</surname><given-names>SC Jr</given-names></name><name><surname>Pollack</surname><given-names>CV Jr</given-names></name><etal/></person-group><article-title>Clopidogrel to treat patients with non-ST-segment elevation acute
coronary syndromes after hospital discharge</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><issue>7</issue><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">16606819</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dropinski</surname><given-names>J</given-names></name><name><surname>Jakiela</surname><given-names>B</given-names></name><name><surname>Sanak</surname><given-names>M</given-names></name><name><surname>Wegrzyn</surname><given-names>W</given-names></name><name><surname>Biernat</surname><given-names>M</given-names></name><name><surname>Dziedzina</surname><given-names>S</given-names></name><etal/></person-group><article-title>The additive antiplatelet action of clopidogrel in patients with
coronary artery disease treated with aspirin</article-title><source>Thromb Haemost</source><year>2007</year><volume>98</volume><issue>1</issue><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">17598014</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulik</surname><given-names>A</given-names></name><name><surname>Le May</surname><given-names>MR</given-names></name><name><surname>Voisine</surname><given-names>P</given-names></name><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Delarochelliere</surname><given-names>R</given-names></name><name><surname>Naidoo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Aspirin plus clopidogrel versus aspirin alone after coronary
artery bypass grafting: the clopidogrel after surgery for coronary artery
disease (CASCADE) Trial</article-title><source>Circulation</source><year>2010</year><volume>122</volume><issue>25</issue><fpage>2680</fpage><lpage>2687</lpage><pub-id pub-id-type="pmid">21135365</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>AJ</given-names></name><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Tubino</surname><given-names>PV</given-names></name></person-group><article-title>On-pumb versus off-pump coronary artery bypass graft surgery:
what do the evidence show?</article-title><source>Rev Bras Cir Cardiovasc</source><year>2013</year><volume>28</volume><issue>4</issue><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">24598960</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantero</surname><given-names>MA</given-names></name><name><surname>Almeida</surname><given-names>RM</given-names></name><name><surname>Galhardo</surname><given-names>R</given-names></name></person-group><article-title>Analysis of immediate results of on-pump versus off-pump coronary
artery bypass grafting surgery</article-title><source>Rev Bras Cir Cardiovasc</source><year>2012</year><volume>27</volume><issue>1</issue><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22729299</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>EA</given-names></name><name><surname>Locali</surname><given-names>RF</given-names></name><name><surname>Matsuoka</surname><given-names>PK</given-names></name><name><surname>Cherbo</surname><given-names>T</given-names></name><name><surname>Buffolo</surname><given-names>E</given-names></name></person-group><article-title>On-pump coronary artery bypass graft surgery: biochemical,
hormonal and cellular features</article-title><source>Rev Bras Cir Cardivasc</source><year>2011</year><volume>26</volume><issue>4</issue><fpage>525</fpage><lpage>531</lpage></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Chae</surname><given-names>IH</given-names></name><name><surname>Oh</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Off-pump coronary artery bypass may decrease the patency of
saphenous vein grafts</article-title><source>Ann Thorac Surg</source><year>2001</year><volume>72</volume><issue>3</issue><fpage>S1033</fpage><lpage>S1037</lpage><pub-id pub-id-type="pmid">11565721</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>MA</given-names></name><name><surname>Gu</surname><given-names>YJ</given-names></name><name><surname>Boonstra</surname><given-names>PW</given-names></name><name><surname>Grandjean</surname><given-names>JG</given-names></name><name><surname>van Oeveren</surname><given-names>W</given-names></name><name><surname>Ebels</surname><given-names>T</given-names></name></person-group><article-title>Procoagulant activity after off-pump coronary operation: is the
current anticoagulation adequate?</article-title><source>Ann Thorac Surg</source><year>1999</year><volume>67</volume><issue>5</issue><fpage>1370</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">10355414</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>CH</given-names></name><name><surname>Steinbr&#x000fc;chel</surname><given-names>DA</given-names></name></person-group><article-title>Platelet function after coronary artery bypass grafting: is there
a procoagulant activity after offpump compared with on-pump
surgery?</article-title><source>Scand Cardiovasc J</source><year>2003</year><volume>37</volume><issue>3</issue><fpage>149</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">12881156</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyde</surname><given-names>JA</given-names></name><name><surname>Chinn</surname><given-names>JA</given-names></name><name><surname>Graham</surname><given-names>TR</given-names></name></person-group><article-title>Platelets and cardiopulmonary bypass</article-title><source>Perfusion</source><year>1998</year><volume>13</volume><issue>6</issue><fpage>389</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">9881387</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Dehmer</surname><given-names>GJ</given-names></name><name><surname>Hirshfeld</surname><given-names>JW</given-names></name><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Spertus</surname><given-names>JA</given-names></name><collab>American College of Cardiology Foundation Appropriateness Criteria
Task Force</collab><collab>Society for Cardiovascular Angiography and Interventions</collab><collab>Society of Thoracic Surgeons</collab><collab>American Association for Thoracic Surgery</collab><collab>American Heart Association, and the American Society of Nuclear
Cardiology Endorsed by the American Society of Echocardiography</collab><collab>Heart Failure Society of America</collab><collab>Society of Cardiovascular Computed Tomography</collab></person-group><article-title>ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for
Coronary Revascularization: a report by the American College of Cardiology
Foundation Appropriateness Criteria Task Force, Society for Cardiovascular
Angiography and Interventions, Society of Thoracic Surgeons, American
Association for Thoracic Surgery, American Heart Association, and the
American Society of Nuclear Cardiology Endorsed by the American Society of
Echocardiography, the Heart Failure Society of America, and the Society of
Cardiovascular Computed Tomography</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><issue>6</issue><fpage>530</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">19195618</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>JH</given-names></name><name><surname>Stoner</surname><given-names>JA</given-names></name><name><surname>Owora</surname><given-names>A</given-names></name><name><surname>Mathew</surname><given-names>ST</given-names></name><name><surname>Thadani</surname><given-names>U</given-names></name></person-group><article-title>Evidence for using clopidogrel alone or in addition to aspirin in
post coronary artery bypass surgery patients</article-title><source>Am J Cardiol</source><year>2009</year><volume>103</volume><issue>12</issue><fpage>1687</fpage><lpage>1693</lpage><pub-id pub-id-type="pmid">19539077</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Chew</surname><given-names>DP</given-names></name><name><surname>Hirsch</surname><given-names>AT</given-names></name><name><surname>Ringleb</surname><given-names>PA</given-names></name><name><surname>Hacke</surname><given-names>W</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Superiority of clopidogrel versus aspirin in patients with prior
cardiac surgery</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>3</issue><fpage>363</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">11157686</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Mehta</surname><given-names>SR</given-names></name><name><surname>Peters</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Lakkis</surname><given-names>N</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Benefits and risks of the combination of clopidogrel and aspirin
in patients undergoing surgical revascularization for non-ST-elevation acute
coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent
ischemic Events (CURE) Trial</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>10</issue><fpage>1202</fpage><lpage>1208</lpage><pub-id pub-id-type="pmid">15313956</pub-id></element-citation></ref></ref-list></back></article>